IQVIA
IQVIA questions whether 340B claims identifiers can be used successfully to implement the Inflation Reduction Act's Medicare drug price negotiation and drug inflation rebate provisions.

Study Raises Questions About Using 340B Claim Modifiers to Implement Medicare Drug Price Negotiation and Inflation Rebate Provisions

New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B price on the same drug.

“340B modifiers provide visibility to 340B transactions in some segments of payers, pharmacies, and products but not others,” IQVIA said in the Feb. 21 white paper. “Further thought needs to be given to determine the optimal methods for consistently identifying 340B drugs in order to support implementation of non-duplication and inflationary rebate provisions” of last year’s Inflation Reduction Act.

New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B price on the same drug.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer